Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.250
-0.020 (-1.57%)
At close: Mar 3, 2026, 4:00 PM EST
1.250
0.00 (0.00%)
After-hours: Mar 3, 2026, 4:10 PM EST
Pliant Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Pliant Therapeutics stock have an average target of 3.75, with a low estimate of 1.50 and a high estimate of 10. The average target predicts an increase of 200.00% from the current stock price of 1.25.
Analyst Consensus: Hold
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for Pliant Therapeutics stock from 9 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 9 | 9 | 9 | 9 | 9 | 7 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | +60.00% | Nov 7, 2025 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 10, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $17 → $4 | Buy | Maintains | $17 → $4 | +220.00% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 4, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.50
from -3.47
EPS Next Year
-2.54
from -2.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.50 | -1.45 | ||||
| Avg | -2.50 | -2.54 | ||||
| Low | -2.50 | -6.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.